URN | urn:agi-cas:363-24-6 |
---|---|
Total Entities | 7 |
Connectivity | 9002 |
Name | prostaglandin E2 |
Description | prostaglandine E2 |
Class | Endogenous compound |
Molecular Weight | 352.465080 |
XLogP | 2.800000 |
ChildConcepts | PGD3 |
---|---|
PGD2 | |
PGF2alpha | |
PGA2 | |
8-epi-PGF2alpha | |
8-iso-PGE2 | |
PGD1 |
Pathway | Bradykinin Effects in Inflammation |
---|---|
Platelet Activation via GPCR Signaling | |
Hypothalamic-Pituitary-Adrenal Axis in Acute Phase Response | |
Prostaglandin E2 Receptor Signaling in Neurons | |
Eicosanoids in Myeloid Cell Activation | |
Eicosanoids in Inflammation | |
Prostaglandin E2 and Histamine in Gastric Acid Secretion | |
Mast-Cells De Novo Synthesized Mediators via IgE Independent Signaling | |
Vasodilation Activation | |
Vascular Endothelial Cell Activation by Cytokines | |
Vascular Endothelial Cell Activation by Blood Coagulation Factors | |
Vascular Endothelial Cell Activation by Growth Factors | |
Lipolysis Regulation in Adipocyte | |
Nociception Expression Targets Signaling | |
Vascular Motility | |
Ca2+ Flux Regulation | |
PTGER1/4 -> Vascular Motility | |
PTGER2/3 -> Vascular Motility | |
PTGER2/3 -> Inflammation-Related Expression Targets | |
IL6 Expression Targets -> Nociception | |
IL1B Expression Targets -> Nociception | |
NMDA Receptors -> Ca2+/CREB Activation/PGE2 Synthesis | |
Luteinizing Hormone in Oocyte Meiotic Resumption | |
Prostaglandins Role in Sleep Regulation | |
Hematopoietic Cell Lineage: B-cell | |
Arterial Hypertension | |
T-Cells Differentiation Block in Psoriasis | |
Metastatic Colorectal Cancer | |
Goblet-Cell Related Mucus Secretion in Asthma | |
Osteoclast Activation in Gout | |
Monocytes Function in Gout | |
IL1B Induced Arthralgia | |
Vascular Endothelial Cell Vasodilation in Brain | |
Dopamine Action in CSD Progression | |
Postsynaptic Neuron Activation | |
eNOS (NOS3) Activation via Prostaglandin E2 and Histamine | |
Prostaglandin E2 Synthesis Activation via Glutamate in Familial Hemiplegic Migraine | |
Neuroinflammation in Amyotrophic Lateral Sclerosis | |
Local Estrogen Production in Endometriosis | |
Angiogenesis in Endometriosis | |
BMP Signaling Impairment in Granulosa Cell in POF | |
HPV E5 Regulates EDNRA and EGFR Signaling Pathway in Keratinocytes | |
Sertoli Cells Dysfunction Causes Male Infertility | |
Aryl Hydrocarbon Receptor/Arachidonic Acid Metabolites Signaling | |
Valdecoxib Induced Ischemic Disease | |
EGFR Transactivation in Cancer and Non-Cancer Cells | |
IL23A and IL17A Provoke Cancer-Associated Inflammation | |
HIF1A in Vasculogenic Mimicry of Cancer | |
VEGFA Dependent Angiogenesis in Cancer | |
Tumor Infiltrating Macrophages in Cancer Progression and Immune Escape | |
Myeloid Derived Suppressor Cells in Cancer Immune Escape | |
Arachidonic Acid Metabolism | |
IL1B -> PGE2 Expression Targets | |
ROS and RNS in Vasoconstriction and Vasodilation Regulation | |
PPAR Psoriasis | |
1_Differentiation of psoriatic T cells | |
1_TNF and IL1B provoke ECM degradation in osteoarthritis | |
1_Local estrogen production stimulates ectopic endometrium proliferation | |
3_Enhanced angiogenesis in endometriosis | |
4_Endothelial cells repress vasoconstriction in hypertension | |
3_1_Mucus accumulation in asthma | |
4_Mucin hyperproduction in goblet and mucous cells in COPD | |
1_1_Glutamate overload enforced prostaglandins and NO synthesis in neurons | |
1_2_Glutamate overload and NO-mediated vasodilation | |
Differentiation of psoriatic T cells |
MedScan ID | 1215412 |
---|
Alias | Prostaglandins E2 |
---|---|
propess | |
L-PGE2 | |
[1-14C]prostaglandin E2 | |
(e,z)-(1r,2r, 3r)-7-[3-hydroxy-2-[(3s)-(3-hydroxy-1-octenyl)]-5-oxocyclopentyl]- 5-heptenoic acid | |
Prostaglandin E2 | |
urinary prostaglandin E2 | |
prostin E2 vaginal cream | |
[12C]prostaglandin E2 | |
(e,z)-(1r,2r, 3r)-7-(3-hydroxy-2-((3s)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)- 5-heptenoic acid | |
prostaglandin E II | |
U 12062 | |
cerviprime | |
prostine | |
prostaglandin (PG) E2 | |
Prepidil Gel | |
(e,z)-(1r,2r,3r,5s)-7-(3-hydroxy-2-((3s)-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid | |
prostin E2 tab | |
363-24-6 | |
Prostin | |
postaglandin E2 | |
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoate | |
PG007 | |
dinoprostone gel | |
Prostaglandin PGE2 | |
l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoate | |
NSC 165560 | |
minprostin e 2 | |
U-12062 | |
(e,z)-(1r,2r,3r,5s)-7-[3-hydroxy-2-[(3s)-(3-hydroxy-1-octenyl]-5-oxocyclopentyl]-5-heptenoic acid | |
(15S)-Prostaglandin E2 | |
(5z,11a,13e,15s)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid | |
uPGE2 | |
Prepidil | |
Dinoprostone | |
Dinoprostona | |
(e,z)-(1r,2r,3r,5s)-7-(3-hydroxy-2-((3s)-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoate | |
7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoic acid | |
prostaglandin (PG) E2alpha | |
(e,z)-(1r,2r,3r,5s)-7-[3-hydroxy-2-[(3s)-(3-hydroxy-1-octenyl]-5-oxocyclopentyl]-5-heptenoate | |
Dinoproston | |
(5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oate | |
dinoprostone sodium | |
L-Prostaglandin E2 | |
(5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid | |
Cervidil | |
uPGE(2) | |
primiprost | |
prostin R | |
7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoate | |
11,15 dihydroxy 9 oxoprosta 5,13 dien 1 oic acid | |
prostin 3 | |
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic | |
U,12, 062 | |
prostarmon E | |
PGE2 | |
ORG2634 | |
dinoprostin | |
(e,z)-(1r,2r, 3r)-7-(3-hydroxy-2-((3s)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)- 5-heptenoate | |
l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid | |
prostin E2 vaginal gel | |
(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid | |
(5z,13e)-(15s)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate | |
(5z,13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoate | |
minprostin | |
PGE2alpha | |
(e,z)-(1r,2r, 3r)-7-[3-hydroxy-2-[(3s)-(3-hydroxy-1-octenyl)]-5-oxocyclopentyl]- 5-heptenoate | |
Dinoprostonum | |
Prostenon | |
EINECS 206-656-6 | |
(5z,11a,13e,15s)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oate | |
Prostaglandin E2 alpha | |
Prostin E2 | |
PGE(2) | |
prandin E2 | |
prostaglandine E2 alpha | |
L-Prostaglandine E2 | |
prostaglandine E2 | |
prostaglandine (PG) E2alpha | |
prostaglandine (PG) E2 | |
prostaglandin gel | |
prostaglandin pessary | |
minprostin E2 | |
Minprositin E2 | |
minproistin E2 | |
5-heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl) | |
5-heptenoic acid,7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, l |
CAS ID | 363-24-6 |
---|
Reaxys ID | 2224720 |
---|---|
2224721 | |
2224722 | |
2224723 | |
2224724 | |
2421225 | |
2705862 | |
2705863 | |
2819704 | |
2819705 | |
2819706 | |
2819707 | |
2819708 | |
2819709 | |
2819710 | |
2819711 | |
2819712 | |
2819713 | |
2950614 | |
2950615 | |
2950616 | |
2950617 | |
2950618 | |
2950619 | |
2950620 | |
2950621 | |
2950622 | |
2950623 | |
3037904 | |
3037905 | |
3037906 | |
4152491 | |
4152492 | |
4152493 | |
4152494 | |
4152495 | |
4709355 |
ChEBI ID | 15551 |
---|
PharmaPendium ID | Dinoprostone |
---|
HMDB ID | HMDB01220 |
---|---|
HMDB12580 | |
HMDB12601 | |
HMDB12638 | |
HMDB12777 | |
HMDB12855 |
KEGG ID | C00584 |
---|
InChIKey | XEYBRNLFEZDVAW-ARSRFYASSA-N |
---|
Molecular Formula | C20H32O5 |
---|
PubChem SID | 134973974 |
---|---|
152904 |
PubChem CID | 5280360 |
---|
IUPAC Name | (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-keto-cyclopentyl]hept-5-enoic acid |
---|
Rotatable Bond Count | 12 |
---|
PharmaPendium Name | Dinoprostone |
---|